The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Prevalence of CD44+/CD24−/low Cells in Breast Cancer May Not Be Associated with Clinical Outcome but May Favor Distant Metastasis
Abstract
Purpose: Breast cancer is composed of phenotypically diverse populations of cancer cells. The ability to form breast tumors has been shown by in vitro/in vivo studies to be restricted to epithelial tumor cells with CD44+/CD24−/low characteristics. Validation of these findings with respect to detection in clinical samples, prognosis, and clinical relevance is in demand. Experimental Design: We investigated breast cancer tissues for the prevalence of CD44+/CD24−/low tumor cells and their prognostic value. The study included paraffin-embedded tissues of 136 patients with and without recurrences. In addition, a breast cancer progression array with normal, carcinoma in situ, and carcinoma tissues was analyzed. We applied double-staining immunohistochemistry for the detection of CD44+/CD24−/low cells. Evaluation was by microscopic pathologic inspection and automated image analysis. Results: CD44+/CD24−/low cells ranged from 0% to 40% in normal breast and from 0% to 80% in breast tumor tissues. The prevalence of CD44+/CD24−/low tumor cells in 122 tumors was ≤10% in the majority (78%) of cases and >10% in the remainder. There was no significant correlation between CD44+/CD24−/low tumor cell prevalence and tumor progression. Although recurrences of tumors with high percentages of CD44+/CD24−/low tumor cells were mainly distant, preferably osseous metastasis, there was no correlation with the event-free and overall survival. There was no influence on the response to different treatment modalities. Conclusions: Our findings suggest that the prevalence of CD44+/CD24−/low tumor cells in breast cancer may not be associated with clinical outcome and survival but may favor distant metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Therapeutic implications of cancer stem cells
Al-Hajj, M., Becker, M. W., Wicha, M., Weissman, I., & Clarke, M. F. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2003.11.007 · Cited by 566
Stem cells and breast cancer: A field in transit
Smalley, M., & Ashworth, A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1212 · Cited by 380
Breast cancer stem cells revealed
Dick, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830967100 · Cited by 319
Zohar, R., Suzuki, N., Suzuki, K., Arora, P., Glogauer, M., McCulloch, C. A. G., & Sodek, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<118::aid-jcp13>3.0.co;2-y · Cited by 276
Tzukerman, M., Rosenberg, T., Ravel, Y., Reiter, I., Coleman, R., & Skorecki, K. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235551100 · Cited by 80
Double Autoimmunostaining with Glycine Treatment
Hasui, K., Takatsuka, T., Sakamoto, R., et al. (2003) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540305100907 · Cited by 26
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
The biology and role of CD44 in cancer progression: Therapeutic implications
Chen, C., Zhao, S., Karnad, A., & Freeman, J. W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0605-5 · Cited by 1,245
Fillmore, C. M., & Kuperwasser, C. (2008) · Breast Cancer Research · doi:10.1186/bcr1982 · Cited by 1,033
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
Zhou, B.-B. S., Zhang, H., Damelin, M., Geles, K. G., Grindley, J. C., & Dirks, P. B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2137 · Cited by 841
Metadata
- Authors
- Abraham, B. K., Fritz, P., McClellan, M., Hauptvogel, P., Athelogou, M., & Brauch, H.
- Venue
- Clinical Cancer Research
- Published
- 2005-02-01
- Volume
- 11
- Issue
- 3
- Pages
- 1154-1159
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2138240181
- Cited by
- 527
- References
- 11
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of CD44+/CD24−/low Cells in Breast Cancer May Not Be Associated with Clinical Outcome but May Favor Distant Metastasis. https://app.cochat.ai/papers/10.1158/1078-0432.1154.11.3
- The paper
- Abraham, B. K., Fritz, P., McClellan, M., Hauptvogel, P., Athelogou, M., & Brauch, H. (2005). Prevalence of CD44+/CD24−/low Cells in Breast Cancer May Not Be Associated with Clinical Outcome but May Favor Distant Metastasis. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.1154.11.3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.